These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 1846250)

  • 1. A randomized prospective trial of anti-Tac monoclonal antibody in human renal transplantation.
    Kirkman RL; Shapiro ME; Carpenter CB; McKay DB; Milford EL; Ramos EL; Tilney NL; Waldmann TA; Zimmerman CE; Strom TB
    Transplantation; 1991 Jan; 51(1):107-13. PubMed ID: 1846250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts.
    Soulillou JP; Cantarovich D; Le Mauff B; Giral M; Robillard N; Hourmant M; Hirn M; Jacques Y
    N Engl J Med; 1990 Apr; 322(17):1175-82. PubMed ID: 2157982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of acute rejection episodes with an anti-interleukin 2 receptor monoclonal antibody. I. Results after combined pancreas and kidney transplantation.
    Cantarovich D; Le Mauff B; Hourmant M; Dantal J; Baatard R; Denis M; Jacques Y; Karam G; Paineau J; Soulillou JP
    Transplantation; 1994 Jan; 57(2):198-203. PubMed ID: 8310507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of yttrium-90-labeled anti-Tac antibody in primate xenograft transplantation.
    Cooper MM; Robbins RC; Goldman CK; Mirzadeh S; Brechbiel MW; Stone CD; Gansow OA; Clark RE; Waldmann TA
    Transplantation; 1990 Nov; 50(5):760-5. PubMed ID: 2238051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of acute cellular rejection with T10B9.1A-31 or OKT3 in renal allograft recipients.
    Waid TH; Lucas BA; Thompson JS; Brown SA; Munch L; Prebeck RJ; Jezek D
    Transplantation; 1992 Jan; 53(1):80-6. PubMed ID: 1531095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential IL-2 receptor expression in renal allograft recipients treated with an anti-IL-2-receptor antibody.
    Ramos EL; Milford EL; Kirkman RL; Tilney NL; Strom TB; Shapiro ME; Waldmann TA; Wood IG; Rollins MR; Carpenter CB
    Transplantation; 1989 Sep; 48(3):415-20. PubMed ID: 2571203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prophylactic use of monoclonal anti-IL-2 receptor antibody in cadaveric renal transplantation.
    Carpenter CB; Kirkman RL; Shapiro ME; Milford EL; Tiney NL; Waldmann TA; Zimmerman CE; Ramos EL; Strom TB
    Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):54-7. PubMed ID: 2683758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction immunosuppression with antilymphocyte globulin or OKT3 in cadaver kidney transplantation. Results of a single institution prospective randomized trial.
    Hanto DW; Jendrisak MD; So SK; McCullough CS; Rush TM; Michalski SM; Phelan D; Mohanakumar T
    Transplantation; 1994 Feb; 57(3):377-84. PubMed ID: 8108873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved efficacy of basiliximab over antilymphocyte globulin induction therapy in paediatric renal transplantation.
    Clark G; Walsh G; Deshpande P; Koffman G
    Nephrol Dial Transplant; 2002 Jul; 17(7):1304-9. PubMed ID: 12105256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoclonal antibody OKT3 therapy in pediatric kidney transplant recipients.
    Leone MR; Barry JM; Alexander SR; Melvin T; Striegel J; Reller K; Henell KR; Kimball J; Funnell MB; Goldstein G
    J Pediatr; 1990 May; 116(5):S86-91. PubMed ID: 2139465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved results using OKT3 as induction immunosuppression in renal allograft recipients with delayed graft function.
    Benvenisty AI; Cohen D; Stegall MD; Hardy MA
    Transplantation; 1990 Feb; 49(2):321-7. PubMed ID: 2137654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Excellent outcome with a calcium channel blocker-supplemented immunosuppressive regimen in cadaveric renal transplantation. A potential strategy to avoid antibody induction protocols.
    Suthanthiran M; Haschemeyer RH; Riggio RR; Adubor C; Friedman GS; Cheigh JS; Wang JC; Fotino M; Stubenbord WT; Saal SD
    Transplantation; 1993 May; 55(5):1008-13. PubMed ID: 8497873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, placebo-controlled trial with anti-interleukin-2 receptor antibody for immunosuppressive induction therapy after liver transplantation.
    Langrehr JM; Glanemann M; Guckelberger O; Klupp J; Neumann U; Machens C; Lohmann R; Knoop M; Lobeck H; Schlag H; Keck H; Settmacher U; Bechstein WO; Neuhaus PJ
    Clin Transplant; 1998 Aug; 12(4):303-12. PubMed ID: 9686324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective randomized comparison of quadruple versus triple therapy for first cadaver transplants with immediate function.
    Slakey DP; Johnson CP; Callaluce RD; Browne BJ; Zhu YR; Roza AM; Adams MB
    Transplantation; 1993 Oct; 56(4):827-31. PubMed ID: 8212201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. OKT3 treatment of steroid-resistant renal allograft rejection.
    Thistlethwaite JR; Gaber AO; Haag BW; Aronson AJ; Broelsch CE; Stuart JK; Stuart FP
    Transplantation; 1987 Feb; 43(2):176-84. PubMed ID: 3544373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized prospective trial of anti-Tac monoclonal antibody in human renal transplantation.
    Kirkman RL; Shapiro ME; Carpenter CB; McKay DB; Milford EL; Ramos EL; Tilney NL; Waldmann TA; Zimmerman CE; Strom TB
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1066-7. PubMed ID: 1989150
    [No Abstract]   [Full Text] [Related]  

  • 18. Early use of OKT3 monoclonal antibody in renal transplantation to prevent rejection.
    Norman DJ; Shield CF; Barry J; Bennett WM; Henell K; Kimball J; Funnell B; Hubert B
    Am J Kidney Dis; 1988 Feb; 11(2):107-10. PubMed ID: 3277400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolongation of primate renal allograft survival by anti-Tac, an anti-human IL-2 receptor monoclonal antibody.
    Reed MH; Shapiro ME; Strom TB; Milford EL; Carpenter CB; Weinberg DS; Reimann KA; Letvin NL; Waldmann TA; Kirkman RL
    Transplantation; 1989 Jan; 47(1):55-9. PubMed ID: 2643232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CMV infections after two doses of daclizumab versus thymoglobulin in renal transplant patients receiving mycophenolate mofetil, steroids and delayed cyclosporine A.
    Abou-Ayache R; Büchler M; Lepogamp P; Westeel PF; Le Meur Y; Etienne I; Lobbedez T; Toupance O; Caillard S; Goujon JM; Bergougnoux L; Touchard G
    Nephrol Dial Transplant; 2008 Jun; 23(6):2024-32. PubMed ID: 18199693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.